Dashboard
Manage Tickers

CDNA CareDx, Inc.

Nasdaq caredx.com


$ 15.07 $ 0.31 (2.09 %)    

Thursday, 16-Oct-2025 09:48:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.48 $ 0.27 (0.04 %)
DIA $ 463.41 $ 0.04 (0.01 %)
SPY $ 666.69 $ -0.18 (-0.03 %)
TLT $ 90.66 $ 0.15 (0.17 %)
GLD $ 391.31 $ 0.15 (0.04 %)
$ 14.7
$ 14.74
$ 15.00 x 100
$ 15.13 x 100
$ 14.74 - $ 15.14
$ 10.96 - $ 26.85
1,292,084
na
782.44M
$ 1.48
$ 13.46
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 10-28-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 02-28-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-06-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-22-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 06-09-2017 03-31-2017 10-Q
35 04-21-2017 12-31-2016 10-K
36 11-15-2016 09-30-2016 10-Q
37 08-22-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 03-29-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

caredx-to-feature-new-ivd-products-and-ivdr-certification-for-alloseq-tx-and-qtype-at-ashi-2025-annual-meeting
CareDx To Feature New IVD Products And IVD...
10/06/2025 11:12:34

Furthers Global Leadership in Donor Organ and Transplant Recipient HLA TypingCareDx, Inc. (NASDAQ:CDNA) – The Transplant Compan...

4-analysts-assess-caredx-what-you-need-to-know
4 Analysts Assess CareDx: What You Need To...
09/23/2025 14:02:11

btig-reiterates-buy-on-caredx-maintains-22-price-target
BTIG Reiterates Buy on CareDx, Maintains $...
09/23/2025 09:56:52

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

btig-reiterates-buy-on-caredx-maintains-22-price-target
BTIG Reiterates Buy on CareDx, Maintains $...
09/12/2025 10:33:46

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

caredx-urges-noridian-to-preserve-coverage-for-combination-and-personalized-molecular-testing-opposes-surveillance-limits-and-bundled-payments-in-draft-lcd-dl40060
CareDx Urges Noridian To Preserve Coverage...
09/02/2025 20:05:21

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, developme...

caredx-submits-comment-letter-on-draft--local-coverage-determination-policy
CareDx Submits Comment Letter On Draft Lo...
09/02/2025 20:03:53

caredx-battles-reimbursement-uncertainty-as-market-overlooks-long-term-potential
CareDx Battles Reimbursement Uncertainty A...
08/26/2025 17:08:11

CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant so...

this-actuate-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-tuesday
This Actuate Therapeutics Analyst Begins C...
08/26/2025 11:49:01

william-blair-initiates-coverage-on-caredx-with-market-perform-rating
William Blair Initiates Coverage On CareDx...
08/26/2025 11:32:23

William Blair analyst Andrew Brackmann initiates coverage on CareDx (NASDAQ:CDNA) with a Market Perform rating.

wells-fargo-maintains-equal-weight-on-caredx-lowers-price-target-to-14
Wells Fargo Maintains Equal-Weight on Care...
08/08/2025 15:24:20

Wells Fargo analyst Brandon Couillard maintains CareDx (NASDAQ:CDNA) with a Equal-Weight and lowers the price target from $1...

caredx-names-nathan-smith-as-cfo
CareDx Names Nathan Smith As CFO
08/06/2025 21:10:25

caredx-narrows-fy2025-sales-guidance-from-365000m-375000m-to-367000m-373000m-vs-370794m-est
CareDx Narrows FY2025 Sales Guidance from ...
08/06/2025 20:37:05

CareDx (NASDAQ:CDNA) narrows FY2025 sales outlook from $365.000 million-$375.000 million to $367.000 million-$373.000 million v...

caredx-q2-adj-eps-010-misses-012-estimate-sales-86679m-miss-90563m-estimate
CareDx Q2 Adj. EPS $0.10 Misses $0.12 Esti...
08/06/2025 20:05:55

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 18....

caredx-publishes-koar-study-in-american-journal-of-transplantation-showcasing-allosure-dd-cfdna-for-enhanced-kidney-rejection-detection-and-biopsy-guidance
CareDx Publishes KOAR Study In American Jo...
08/06/2025 17:09:48

KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant SurveillanceAl...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

caredx-presents--several-high-impact-studies-and-digital-health-innovations-by-independent-research-teams-at-the-2025-world-transplant-congress-demonstrating-advances-in-artificial-intelligence-predictive-diagnostics-transplant-access-and-organ-specific-innovation
CareDx Presents Several High-Impact Studi...
07/31/2025 20:36:30

Core News & Articles
'HHS Finds Systemic Disregard for Sanctity...
07/21/2025 17:17:03

https://www.hhs.gov/press-room/hrsa-to-reform-organ-transplant-system.html#:~:text=It%20found%3A,serious%20ethical%20and%20lega...

craig-hallum-maintains-buy-on-caredx-lowers-price-target-to-26
Craig-Hallum Maintains Buy on CareDx, Lowe...
07/18/2025 15:32:17

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and lowers the price target from $40 to $26.

caredx-announces-release-of-proposed-draft-local-coverage-determination-related-to-molecular-testing-for-solid-organ-allograft-rejection
CareDx Announces Release Of Proposed Draft...
07/18/2025 12:03:42

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
07/17/2025 17:06:01

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION